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Abstract
Malignant pleural mesotheliomas (MPMs) are usually
wild type for the p53 gene but contain homozygous
deletions in the INK4A locus that encodes p14ARF, an
inhibitor of p53–MDM2 interaction. Previous findings
suggest that lack of p14ARF expression and the pres-
ence of SV40 large T antigen (L-Tag) result in p53 in-
activation in MPM. We did not detect SV40 L-Tag mRNA
in either MPM cell lines or primary cultures, and treat-
ment of p14ARF-deficient cells with cisplatin (CDDP)
increased both total and phosphorylated p53 and en-
hanced p53 DNA-binding activity. On incubation with
CDDP, levels of positively regulated p53 transcrip-
tional targets p21WAF, PIG3, MDM2, Bax, and PUMA
increased in p14ARF-deficient cells, whereas negatively
regulated survivin decreased. Significantly, p53-
induced apoptosis was activated by CDDP in p14ARF-
deficient cells, and treatment with p53-specific siRNA
rendered them more CDDP-resistant. p53 was also
activated by: 1) inhibition of MDM2 (using nutlin-3);
2) transient overexpression of p14ARF; and 3) targeting
of survivin using antisense oligonucleotides. How-
ever, it is noteworthy that only survivin downregula-
tion sensitized cells to CDDP-induced apoptosis. These
results suggest that p53 is functional in the absence
of p14ARF in MPM and that targeting of the down-
stream apoptosis inhibitor survivin can sensitize to
CDDP-induced apoptosis.
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Introduction
Malignant pleural mesothelioma (MPM) is a cancer of meso-
thelial cells that line lung pleural membranes. The incidence
of MPM is highly associated with exposure to asbestos [1].
Due to the long latency period of the disease, projections
suggest that the number of MPM-related deaths in western
Europe will double each year until 2018 [2]. MPM is a
treatment-resistant tumor with a very poor prognosis [3].
Although there is no standard treatment for MPM, current
multimodality interventions include combined chemotherapy
with cisplatin (CDDP) and pemetrexed or gemcitabine [4].
p53 has been termed as the ‘‘guardian of the genomes’’
because it mediates the effects of DNAdamage and, depending
on cellular context, induces cell cycle arrest and DNA repair or
death. p53-induced apoptosis involves the transcription of
proapoptotic genes (such as Bax and PUMA) and the repres-
sion of antiapoptotic genes (such as survivin and Bcl-2) [5]. p53
also displays transcription-independent proapoptotic functions
by interacting directly with Bcl-xL and Bax and by inducing
the mitochondrial pathway of apoptosis [6]. In resting cells,
p53 regulates its own expression by inducing the synthesis of
the inhibitor MDM2, which binds p53 and blocks DNA trans-
activation. MDM2 also has E3 ligase activity that promotes
the ubiquitination and degradation of p53 through the 26S
proteosome [7]. Recognition of DNA damage leads to the sta-
bilization of p53 through posttranslational modifications such
as phosphorylation, acetylation, and sumoylation, which inter-
fere with p53–MDM2 interaction [5]. During oncogenic stress,
inhibition of p53 by MDM2 is also abrogated by the tumor-
suppressor protein p14ARF, which binds to MDM2, sequesters
it in the nucleolus, and blocks its E3 ligase activity [8]. p14ARF
expression has also been described to play a role in the re-
sponse of p53 to DNA damage [9,10], although these results
are controversial [11,12].
Most cancers have evolved mechanisms to deregulate p53,
and inactivating mutations in the p53 gene arise in approxi-
mately 50% of human tumors [13]. In those tumors with wild-
type p53, there are often alterations in genes that regulate
p53, such as amplifications of the MDM2 gene or, as is the
case for MPM, homozygous deletions in the INK4A locus en-
coding p14ARF [14]. Yang et al. [15] proposed that p53 is in-
active in MPM cells as a result of p14ARF deficiency because
MPM cells were sensitive to infection by the oncolytic virus
ONYX-015. In addition, the SV40 large T antigen (L-Tag) has
been proposed to block p53 function in MPM [16]; however,
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recent studies question the frequency of SV40 infection in
MPM tumors [17].
In the present study, we investigated the status of p53 in
MPM cells lacking p14ARF. Our findings suggest that p53
is functional in MPM in the absence of p14ARF and that it is
activated by DNA damage.
Materials and Methods
Cell Culture
The MPM cell lines SPC212, ZL5, ZL55, and ZL34 were
generated in our laboratory and have been described pre-
viously [18]. The Met5A cell line (Dr. J. F. Lechner; NCI,
Bethesda, MD) corresponds to normal human mesothelial
cells immortalized by transfection with an SV40 early region
plasmid [19], and the NCI-H28 cell line was obtained from
ATCC (Manassas, VA). Primary MPM cultures were derived
from MPM pleural effusions, as described previously [18],
and were characterized by the positive staining of cells with
antibodies specific for calretinin. All cells were grown in
RPMI 1640 (Sigma, St. Louis, MI) supplemented with 2 mM
L-glutamine, 1 mM sodium pyruvate, 10% fetal bovine serum,
and 1% (wt/vol) penicillin/streptomycin at 37jC in a humidi-
fied atmosphere containing 5% CO2. Where indicated, CDDP
(Bristol-Myers Squibb AG, Baar, Switzerland) and nutlin-3
(Alexis Corporation, Lausen, Switzerland) were added. Nutlin-
3 was dissolved in dimethyl sulfoxide (DMSO) and compared
to cells treated with similar volumes of DMSO alone.
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR)
RNA was isolated from cell lines using the RNeasy kit
(Qiagen, Basel, Switzerland), according to the manufac-
turer’s instructions. One microgram of RNA was used in
RT-PCR using the One-Step RT-PCR kit (Qiagen). The
following primers were used: SV40 T antigen: 5V primer (5V-
AGTCCTCGAGTCTTTGCAGCTAATGGACCT) and 3V
primer (5V-AGTCTCTAGATCCTTTGTGGTGTAAATAGC);
p14ARF: 5V primer (5V-TGCTCACCTCTGGTGCCAAAG) and
3V primer (5V-TGGTCTTCTAGGAAGCGGCTG); GAPDH:
5V primer (5V-GAGTCAACGGATTTGGTCGT) and 3V primer
(5V-TGACAAAGTGGTCGTTGAGG).
PCR cycle conditions were as follows: 35 cycles of 94jC
for 40 seconds, 58jC for 40 seconds, and 72jC for 40 sec-
onds for SV40 L-Tag; and 28 cycles of 94jC for 30 seconds,
64jC for 30 seconds, and 72jC for 50 seconds for p14ARF
and GAPDH. Ten microliters of PCR products was analyzed
by electrophoresis on 2.5% agarose gels, and GAPDH band
was used as standardized control.
p53 DNA-Binding Activity
Nuclear extracts were prepared using the Nuclear Extract
kit (Active Motif, Carlsbad, CA), and p53 DNA-binding activity
was assayed using the TransAM p53 kit (Active Motif),
according to the manufacturer’s instructions. Binding to p53
target DNA sequence was measured by colorimetric assay,
and absorbance was read at 450 nm. Samples were per-
formed in quadruplicate, and the mean and standard devia-
tions were calculated. Experiments were performed in
triplicate, and representative data are shown.
p53 Sequencing
DNA sequencing was performed on DNA isolated from
SPC212 cells using Affymetrix p53 Gene Chip Array and Se-
quencing Analysis (BRT Laboratories, Inc., Baltimore, MD).
Western Blot Analysis
Cells were lysed with RIPA buffer (Upstate Cell Signaling
Solutions, Dundee, UK) in the presence of phosphatase in-
hibitors (Sigma) for 30 minutes on ice. Lysates were clarified
by centrifugation (10,000g for 30 minutes at 4jC). Western
blot analysis was performed as described previously [20].
Antibodies with specificity for survivin (R&D Systems, Inc.,
Minneapolis, MN), b-actin (C4; ICN Biomedicals, Inc., Au-
rora, OH), phospho-p53 (ser15) (Cell Signaling Technology,
Inc., Beverly, MA), p14ARF (C18), p21WAF (H-164), p53 (DO-
1),MDM2 (N-20), PIG-3 (C20), Bax (N-20), andPUMA (N-19)
(Santa Cruz Biotechnology, Santa Cruz) were used.
Flow Cytometry
Both adherent and floating cells were collected from
samples and washed in phosphate-buffered saline (PBS).
Cells were then fixed in 50% ethanol and incubated with
propidium iodide (PI)/RNase (BD Pharmingen, San Diego
CA) for 15 minutes at room temperature. Alternatively, live
cells were resuspended in binding buffer and stained with
Annexin V–FITC (Calbiochem, Darmstadt, Germany) for
15 minutes at room temperature. Ten thousand events were
analyzed by flow cytometry using a FACScalibur flow cy-
tometer (Becton Dickinson, Mountain View, CA). For PI stain-
ing, doublets and aggregates were excluded by gating, and
Modfit software was used to identify cell populations in dif-
ferent phases of the cell cycle. The percentage of apoptotic
cells was determined after PI or Annexin V labeling by gating
on untreated samples.
Caspase-3–Like Protease Activity
Both adherent and floating cells were collected from
samples and washed in PBS. Caspase-3– like protease
activity in cell lysates was analyzed by colorimetric assay,
according to the manufacturer’s recommendations (Alexis
Corporation). Cleavage of the labeled substrate DEVD-pNA
was monitored at 405 nm using a SPECTRAmax 340 micro-
plate reader (Paul Bucher Analytik und Biotechnologie,
Basel, Switzerland). The caspase-3–like protease activity
in lysates was calculated as fold increase of the absorbance
signal obtained with lysates of untreated (viable) cells kept
under identical conditions.
Transfections
The p14ARF-pcDNA3.1 plasmid was a kind gift from Prof.
Gordon Peters (ICRF, London, UK). p53-specific siRNA and
control siRNA were purchased from Cell Signaling Tech-
nology, Inc., and Dharmacon, Inc. (Chicago, IL), respectively.
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Transfections with plasmids or siRNA were performed with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to
the manufacturer’s recommendations. Cells were plated at a
concentration of 150,000 cells/ml in medium containing 10%
fetal calf serum (FCS) but containing no antibiotics 1 day
before transfection and were transfected for 24 hours using
OptiMEM (Invitrogen). Thereafter, the medium was changed
to a complete medium containing 10% FCS with indicated
concentrations of CDDP for a further 48 hours.
Measurement of Cell Growth
Cell growth was determined using a colorimetric cell
viability assay based on the reduction of the tetrazolium salt
MTT, as described [21]. Cells were plated in quadruplicate
in 96-well plates (7500 cells/well), and absorbance was
measured at 570 nm using a SPECTRAmax 340 microplate
reader. Cell growth was calculated as a percentage of the
absorbance signal obtained with wells of untreated (viable)
cells kept under identical conditions.
Antisense Oligonucleotides
Survivin phosphothioate antisense oligonucleotides with
the sequence 5V-CCCAGCCTTCCAGCTCCTTG-3V targeting
nucleotides 233 to 253 of the survivin mRNA and the control
sequence 5V-CCTAGCCTTCCAGGTCCTAG-3V (mis-
matches underlined) were purchased from Microsynth AG
(Balgoch, Switzerland). Cells were transfectedwithOligofect-
amine (Invitrogen), according to the manufacturer’s protocol.
Cells were plated at a concentration of 150,000 cells/ml 1 day
before transfection and were transfected for 6 hours; the me-
dium was changed, and cells were incubated for a further
48 hours with the indicated concentration of CDDP.
Results
MPM Cells Are Negative for p14ARF Protein Expression
and SV40 L-Tag mRNA
Homozygous deletions in the INK4A locus of MPM occur
at a frequency of at least 70%, resulting in the absence of
p14ARF expression [14]. We investigated p14ARF expression
in five established MPM cell lines and three primary cultures.
Three MPM cell lines (NCI-H28, ZL5, and ZL34) and three
MPM primary cultures (SDM4, SDM5, and SDM6) were
negative for p14ARF mRNA, whereas it could be detected in
SPC212 and ZL55 cells and in an SV40-transformed meso-
thelial cell line, Met5A (Figure 1). However, in contrast to
Met5A cells, no p14ARF protein was detected in any of the
MPM primary cultures and cell lines tested. The presence of
SV40 viral DNA sequences in MPM tumors has given rise
to the suggestion that p53 is inactivated in MPM by the SV40
L-Tag [16]. MPM cell lines and primary cultures were there-
fore tested for SV40 L-Tag mRNA by RT-PCR, but it could
only be detected in the SV40-transformed Met5A cell line.
p53 Can Be Activated in MPM in the Absence of p14ARF
To determine whether p53 is functional in the absence of
p14ARF expression, the status of p53 in MPM cell lines and
primary cultures was investigated in response to CDDP
treatment. The ability of active p53 protein to bind to its target
DNA sequence was measured using an enzyme-linked im-
munosorbent assay (ELISA)–based assay, which demon-
strated that seven of eight MPM cell lines and primary
cultures had increased levels of p53-specific DNA binding
in response CDDP treatment (Figure 2A). In contrast,
SPC212 cells had no detectable p53 activity, and sequencing
of the p53 gene in these cells revealed a missense mutation
in the hotspot codon 175. ZL55 cells had low levels of p53
DNA-binding activity in response to CDDP, regardless of
p14ARF mRNA expression.
CDDP induced an increase in basal levels of p53 protein
in ZL5, ZL34, and NCI-H28 cells, whereas in SPC212 cells,
the levels of p53 remained consistently high (Figure 2B).
Residue ser15 in the transactivation domain of p53 is phos-
phorylated by protein kinases in response to CDDP, resulting
in the disruption of p53–MDM2 interaction and increased
p53 activity [22,23]. Levels of phospho-ser15 were found
to increase in response to CDDP treatment in all MPM cell
lines, including p53mutant SPC212 cells. These results con-
firm those of others, which demonstrate that both wild-type
and mutant p53 can be phosphorylated on ser15 [24].
In ZL34 cells, the expression of p53 transcriptional targets
MDM2, PIG3, p21WAF, Bax, and PUMA was increased
by CDDP treatment, and similar profiles were observed for
the ZL5 and NCI-H28 cell lines (data not shown), whereas
no induction was seen for SPC212 cells (Figure 2C). Survivin
expression is negatively regulated by p53 [25], and immuno-
blotting demonstrated that, in ZL34 cells, survivin levels de-
creased with increasing concentrations of CDDP, whereas
they remained unchanged in the p53 mutant cell line, SPC212
(Figure 2C). No increase in p14ARF expression was detected
after CDDP treatment (data not shown). Together, these
results suggest that p53-mediated transcription regulation
is fully functional in MPM cells in the absence of p14ARF.
Figure 1. Expression levels of p14ARF in MPM cell lines. RNA was isolated
from MPM primary cultures and cell lines and SV40-transformed Met5A cells,
and RT-PCR was performed to detect p14ARF, SV40 L-Tag and GAPDH
mRNA. Lysates of the same cell lines were analyzed by immunoblotting using
anti-p14ARF C-terminal antibodies. Staining of actin was used as equal
loading control.
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p53-Induced Apoptosis Is Activated in p14ARF-Deficient
MPM Cells
MPM cell lines lacking p14ARF were investigated for their
ability to undergo apoptosis and/or cell cycle arrest in re-
sponse to CDDP. Treatment of MPM cells with CDDP leads
to an increase in the percentage of cells in the sub-G1 phase
of the cell cycle for both ZL5 and ZL34 cell lines, but not
for SPC212 cells (Figure 3, A and B). ZL34 and SPC212
cells, but not ZL5, cells accumulated on the S phase on
CDDP treatment (Figure 3A), which has been observed
previously and occurs independently of p53 status [26].
Apoptosis was also detected by the measurement of An-
nexin V staining and caspase-3– like activity in ZL5 and ZL34
cells in response to CDDP treatment, but not in the p53
mutant SPC212 cell line (Figure 3, C and D).
To demonstrate the role of p53 in CDDP-induced death in
MPM, cells were treated with p53-specific siRNA. Incubation
of ZL34 cells with p53 siRNA resulted in a dose-dependent
decrease in p53, p21WAF, and Bax levels and in increased
survivin relative to control siRNA (Figure 4A). Treatment of
cells with p53 siRNA and 5 mM CDDP also resulted in de-
creased p53, p21WAF, and Bax and in increased survivin rel-
ative to control siRNA (Figure 4A). Transfection of ZL34 cells
with p53-specific siRNA resulted in less CDDP-induced
growth inhibition and decreased apoptosis compared to
control siRNA (Figure 4B). A comparable increase in resis-
tance to CDDP was observed when ZL5 cells were treated
with the p53 inhibitor, pifithrin-a (data not shown). These
results demonstrate that p53 contributes to CDDP-induced
apoptosis in MPM.
Figure 2. p53 is activated in p14ARF-deficient MPM cell lines. (A) MPM primary cultures and cell lines were cultured with 5 M CDDP for 48 hours or were left
untreated. Nuclear extracts were prepared, and binding to the p53 recognition sequence was measured by ELISA, as described in Materials and Methods section.
Data are presented as mean ± SD OD450 nm absorbance values. (B) MPM cell lines were cultured with the indicated concentrations of CDDP for 48 hours. Lysates
were analyzed by immunoblotting using antibodies specific for p53 and phospho-p53 (ser15). Staining of actin was used as loading control. (C) MPM cell lines were
cultured with the indicated concentrations of CDDP for 48 hours. Lysates were analyzed by immunoblotting using antibodies specific for MDM2, PIG3, p21WAF,
Bax, PUMA, and survivin. Staining of actin was used as loading control.
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Inhibition of MDM2 Induces G1 Arrest, But Not Apoptosis
Nutlin-3, a small-molecule inhibitor of MDM2 that binds
the p53-binding pocket and prevents its interaction with p53
[27], was used to investigate the role of MDM2 in the p53
response observed in p14ARF-deficient MPM cells. Incuba-
tion with nutlin-3 resulted in increased levels of p53 and its
transcriptional targets MDM2 and p21WAF in ZL34 cells, sug-
gesting that p53 was activated. However, as reported by
Thompson et al. [28], no increase in phospho-p53 (ser15)
was induced (Figure 5A). The effect of nutlin-3 was p53-
dependent, as expression of p53 target genes was not al-
tered in SPC212 cells. Nutlin-3 treatment induced a G1 cell
cycle arrest in ZL34 cells (Figure 5B), but no caspase-3– like
activity was detected and CDDP-induced apoptosis was
abrogated in the presence of nutlin-3 (Figure 5C). Nutlin-3
had no effect on the sensitivity of SPC212 cells to CDDP,
whereas ZL5 and NCI-H28 behaved similarly to ZL34 (data
not shown). These results suggest that, although inhibition
Figure 3. CDDP induces apoptosis in MPM cell lines. (A) Flow diagrams of untreated cells or of cells treated with 10 M CDDP, fixed, and stained with PI. Panels
represent the proportion of cells in different phases of the cell cycle. Representative data of three independent experiments are shown. (B, C, and D) Cells were
incubated with the indicated concentrations of CDDP for 48 hours. Standard error bars represent the standard deviation of triplicate samples. (B) Percentage of
apoptotic cells in sub-G1 as measured by PI staining and flow cytometry. (C) Percentage of apoptotic cells as measured by Annexin V–FITC staining and flow
cytometry. (D) The caspase-3– like protease activity in cell lysates was calculated as fold increase of the absorbance signal obtained with lysates of untreated cells.
Figure 4. p53-specific death is induced by CDDP in MPM cells. (A) ZL34 cells were transfected with the indicated concentrations of p53 siRNA or control siRNA for
24 hours, or were treated with 50 nM p53 or control siRNA for 24 hours and incubated with 5 M CDDP for a further 48 hours. Lysates were analyzed by
immunoblotting using antibodies specific for p53, p21WAF, Bax, and survivin. Staining of actin was used as loading control. (B) ZL34 cells were transfected with
50 nM p53 siRNA or control siRNA for 24 hours and were subsequently incubated for 48 hours with 5 M CDDP. Cell growth inhibition was calculated as the
percentage relative to untreated controls. Representative data of three independent experiments are shown. Caspase-3– like activity and the percentage of
apoptotic cells were determined by Annexin V staining and flow cytometry, as described in Figure 3. Student’s t test was used to determine the significance
between the p53 siRNA + CDDP group and the control siRNA + CDDP group.
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of MDM2 by nutlin-3 can activate p53-induced cell cycle
arrest in MPM cells, apoptosis is not triggered and CDDP-
induced apoptosis is inhibited.
p53 Activation by Survivin Targeting, But Not p14ARF
Expression, Sensitizes Cells to CDDP-Induced Apoptosis
Others have shown that overexpression of p14ARF using
adenoviruses in MPM cells activates p53 and induces cell
cycle arrest and apoptosis [29]. In contrast, expression of
p14ARF at more physiological levels in several different can-
cer types induced cell cycle arrest but not apoptosis [30].
We introduced p14ARF into p14ARF-deficient cells by transient
transfection and determined their effect on p53 activation
and apoptosis. ZL34 cells expressing p14ARF had increased
levels of p53 compared to the empty vector control; however,
in response to CDDP, p53 levels were only slightly enhanced
by the presence of p14ARF (Figure 6A). In addition, the dif-
ference in caspase-3– like activity between controls and cells
expressing p14ARF treated with CDDP were not significantly
different (Figure 6B). This suggests that expression of p14ARF
does not sensitize cells to CDDP-induced apoptosis.
Survivin is highly expressed in many cancers, including
MPM [31], and is a negative prognostic marker in non–small
cell lung cancer (NSCLC) [32]. Although survivin expression
is negatively regulated by p53 [25], it has also been dem-
onstrated that, in turn, survivin may negatively control p53
function [33,34]. ZL34 cells were incubated with an anti-
sense oligonucleotide 4003 targeting survivin, and a dose-
dependent decrease in survivin protein levels—in addition
to increased levels of p53, phospho-p53 (ser15), p21WAF,
MDM2, and its 60-kDa cleavage product relative to the
mismatch control oligonucleotide 4003mis—was observed
(Figure 6C). A combination of 4003 with CDDP further
increased levels of p53 compared to the mismatch control
(Figure 6D). Treatment with survivin antisense oligonucleo-
tides has been shown by Olie et al. [21] and Xia et al. [35] to
induce apoptosis in NSCLC and MPM cells, respectively.
CDDP-induced caspase-3– like activity was significantly en-
hanced by survivin downregulation in ZL34 cells (Figure 6E ).
Discussion
Previous studies have proposed that p53 is inactive in MPM,
as a result of either p14ARF deletion [15,29,36] or SV40 in-
fection [37]. The aim of the present study was to determine
whether p53 functions in the absence of p14ARF and whether
it contributes to the apoptotic response to CDDP. Studies
using the oncolytic virus ONYX-015, which is thought to
selectively infect those cells expressing nonfunctional p53
[38], showed that MPM cell lines lacking p14ARF were sen-
sitive to viral infection and that expression of exogenous
p14ARF rendered cells more resistant to infection [15]. These
results lead to the conclusion that the p53 pathway is dis-
rupted in MPM cells lacking p14ARF; however, more recent
reports suggest that the ability of ONYX-015 to infect cancer
cells is determined by late viral RNA transport rather than
by p53 status [39,40]. Our study demonstrates that p53
is functional in MPM in the absence of p14ARF, as it can acti-
vate the transcription of target genes and can contribute
to apoptotic response. It is also noteworthy that a recent
large-scale transcriptional analysis of MPM human tumors
revealed that p53 and several of its target genes are upregu-
lated in MPM tumors relative to normal tissues in the ab-
sence of p14ARF [41].
Although studies with mice containing targeted deletions
in p19ARF (the murine equivalent of p14ARF) give evidence for
Figure 5. Nutlin-3 induces p53 activity and cell cycle arrest, but not apoptosis. (A) ZL34 and SPC212 cells were cultured for 24 hours with the indicated
concentrations of nutlin-3. Lysates were analyzed by immunoblotting using antibodies specific for p53, phospho-p53 (ser15), MDM2, and p21WAF. Staining of actin
was used as loading control. (B) ZL34 cells were cultured with 10 M nutlin-3 for 48 hours. Cells were fixed and stained with PI before FACS staining of nuclei.
Representative data of three independent experiments are shown. (C) ZL34 cells were cultured with 10 M nutlin-3 or the same volume of DMSO in the presence
of 1.2 M CDDP for 48 hours. Cells were lysed, and caspase-3– like protease activity was measured as in Figure 3D.
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its role as a tumor suppressor [8,11], it is less clear whether
p19ARF is an essential component of the p53 response to
DNA damage. Khan et al. [10] showed that p53 response to
DNA damage is defective in p19ARF knockout mice, whereas
Schmitt et al. [12] showed that, although loss of p19ARF
completely disabled p53 during lymphomagenesis, p53 was
activated in response to DNA damage in transplanted mu-
rine Em-Myc lymphomas. In the present study, using human
MPM cells deficient in p14ARF expression, we found that,
although transient overexpression of p14ARF activated p53,
it did not sensitize cells to CDDP-induced apoptosis, sug-
gesting that it is not required for the DNA damage response of
p53 in MPM.
The disruption of wild-type p53 has been shown in some
systems to increase resistance to DNA damage–induced
apoptosis [45,46], whereas in other systems, increased sen-
sitivity has been demonstrated [42–44]. It is probable that
the type of response to DNA damage induced in cells where
p53 has been inactivated depends on cell type, genetic
status, and the type of drug used to damage DNA. It is,
however, generally accepted that p53 status contributes to
sensitivity to CDDP [47], and our results are in agreement
with this, as treatment of MPM cells with p53-specific siRNA
increased CDDP resistance to apoptosis.
The small-molecule inhibitor nutlin-3 perturbs p53–MDM2
interaction, resulting in the activation of wild-type p53 and, in
some cases, apoptosis [27]. In MPM cells, nutlin-3 did not
induce apoptosis, and the level of CDDP-induced apoptosis
decreased on combination with nutlin-3. Similarly, a recent
study showed that treatment of cancer cell lines with nutlin-3
induced a strong G1 cell cycle arrest, but only low levels of
apoptosis [48]. One explanation for these findings is that
the cell cycle arrest induced by nutlin-3 has an inhibitory ef-
fect on apoptosis [49,50]. In addition, expression of down-
stream inhibitors could attenuate the apoptotic response
induced by nutlin-3; indeed, recent data have shown that
p53 is directly inhibited by Bcl-xL [6]. Because MPM cells ex-
press high levels of Bcl-xL, these may limit transactivation-
independent apoptosis induction by p53, as well as limit
Bax/Bak oligomerization. We have shown previously that
Figure 6. Survivin antisense oligonucleotides, but not p14ARF expression, activates p53-induced apoptosis. ZL34 cells were transfected with the plasmid pcDNA3
(vector) or pcDNA3-p14ARF (p14ARF) for 6 hours, then the indicated concentrations of CDDP were added for a further 48 hours. Cells were then (A) harvested for
immunoblotting using p14ARF, p53, or actin antibodies, or (B) lysed, and caspase-3– like protease activity was measured using colorimetric assay, as in Figure 3D.
Representative data of three independent experiments are shown. Absorbance values obtained with untreated cells maintained under identical experimental
conditions were taken as 100%. (C) ZL34 cells were transfected with survivin antisense oligonucleotide 4003 or mismatch control 4003mis for 6 hours and were
harvested 20 hours after the start of transfection. Lysates were analyzed by immunoblotting using antibodies specific for survivin, p53, phospho-p53 (ser15),
p21WAF, and MDM2. Staining of actin was used as loading control. (D) ZL34 cells were transfected with transfection reagent alone (OF), survivin antisense
oligonucleotide 4003, or mismatch control 4003mis for 6 hours and then for a further 48 hours with 2.5 M CDDP. Lysates were analyzed by immunoblotting using
antibodies specific for survivin and p53. Staining of actin was used as loading control. (E) ZL34 cells were transfected with 200 nM survivin antisense
oligonucleotide 4003 or the 4003mis mismatch control for 6 hours, and then 1.2 M CDDP was added for a further 48 hours. Cells were lysed and caspase-3–
like protease activity was measured as in Figure 3D. Student’s t test was used to determine the significance between the 4003 + CDDP group and the 4003mis +
CDDP group.
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antisenseoligonucleotides targetingBcl-xL andBcl-2 sensitize
MPM cells to CDDP-induced apoptosis [51], and we are
currently investigating the interaction between Bcl-xL and p53.
Similar to Bcl-xL, survivin is highly expressed in MPM [31]
and in other cancers, where its expression is associated
with aggressive tumor behavior and poor prognosis [52,53].
Survivin inhibits caspase activation [54] and plays an impor-
tant role in cell division, allowing cells to progress through
mitosis [55]. Survivin expression is negatively regulated by
p53; indeed, p53-specific siRNA treatment leads to increased
survivin expression in MPM cells, whichmay contribute to the
observed increased resistance to CDDP. Conversely, survi-
vin has also been shown to negatively regulate p53, either
by inhibiting caspase-mediated cleavage of MDM2 [34] or by
safeguarding against mitotic catastrophe and the resulting
DNA damage [56]. Targeting of survivin with antisense oligo-
nucleotides in MPM resulted in the appearance of a cleav-
age product of MDM2 after antisense treatment, suggesting
that survivin may indeed stabilize MDM2 [34]. In addition,
survivin downregulation also induced p53 phosphorylation,
which suggests that DNA damage response is also activated.
In conclusion, this study demonstrates that p53 is func-
tional in MPM cells and contributes to the apoptotic response
induced by CDDP. It also demonstrates that removal of
downstream inhibitors such as survivin can enhance this re-
sponse more successfully than the disruption of p53–MDM2
interaction by p14ARF or nutlin-3.
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